A newly identified series of compounds demonstrates potent, broad-spectrum antiviral activity against enteroviruses by inhibiting the lipid kinase PI4KIIIβ.
Answers are grounded in this paper and cite their sources.
Supports PI4KIIIβ as antiviral target; animal data leave open human translation.
Rhinovirus (genus enterovirus) infections are responsible for many of the severe exacerbations of asthma and chronic obstructive pulmonary disease. Other members of the genus can cause life-threatening acute neurological infections. There is currently no antiviral drug approved for the treatment of such infections. We have identified a series of potent, broad-spectrum antiviral compounds that inhibit the replication of the human rhinovirus, Coxsackie virus, poliovirus, and enterovirus-71. The mechanism of action of the compounds has been established as inhibition of a lipid kinase, PI4KIIIβ. Inhibition of hepatitis C replication in a replicon assay correlated with enterovirus inhibition.
No takes yet. Share an insight, caveat, or question.
MacLeod et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: